Dr. Stinchcomb’s selected peer-reviewed publications chosen from more than 65 peer-reviewed publications are listed below.

Vehicle composition influence on the microneedle-enhanced transdermal flux of naltrexone hydrochloride. Milewski, M, Stinchcomb, AL.  PharmRes. 28(1):124-34 (2011). PMID: 20577787

Diclofenac delays micropore closure following microneedle treatment in human subjects.  Brogden, Nicole K.; Milewski, Mikolaj; Ghosh, Priyanka; Hardi, Lucia; Crofford, Leslie J.; Stinchcomb, Audra L.  Journal of Controlled Release. 163(2), 220-229 (2012).

Estimation of Maximum Transdermal Flux of Nonionized Xenobiotics from Basic Physicochemical Determinants.  Milewski, Mikolaj; Stinchcomb, Audra L. Molecular Pharmaceutics. 9(7), 2111-2120 (2012).

Development of in vivo impedance spectroscopy techniques for measurement of micropore formation following microneedle insertion.  Brogden NK, Ghosh P, Hardi L, Crofford L, Stinchcomb AL.  JPharmSci.  102(6), 1948-1956 (2013).

Diclofenac enables unprecedented week-long microneedle-enhanced delivery of a skin impermeable medication in humans. Nicole K. Brogden, Stan L. Banks, Leslie J. Crofford, and Audra L. Stinchcomb.   PharmRes.  (DOI) 10.1007/s11095-013-1036-1 (2013).

Characterization of the permeability barrier of human skin in vivo.  F. Pirot, Y.N. Kalia, A.L. Stinchcomb, G. Keating, A.L. Bunge, R.H. Guy.  Proc. Natl. Acad. Sci.  94:  1562-1567 (1997).

Chemical uptake into human stratum corneum in vivo from volatile and non-volatile solvents.  A.L. Stinchcomb, F. Pirot, G. Touraille, A.L. Bunge and R.H. Guy.   Pharmaceutical Research.   16(8):1288-1293 (1999).

Determining dermal absorption parameters in vivo from tape strip data.  M.B. Reddy, A.L. Stinchcomb, R.H. Guy, A.L. Bunge.  Pharmaceutical Research.   19(3):292-298 (2002).

Near-infrared spectrometry for the quantification of dermal absorption of econazole nitrate and 4-cyanophenol.  Medendorp J, Yedluri J, Hammell DC, Ji T, Lodder RA, Stinchcomb AL.  Pharmaceutical Research. 23(4):835-843 (2006).

Near infrared spectrometry for the quantification of human dermal absorption of econazole nitrate and estradiol.  Medendorp J, Paudel K, Lodder RA, Stinchcomb AL.  Pharm. Research. 24(1):186-193 (2007).

Microneedles permit transdermal delivery of a skin-impermeable medication to humans.  Wermeling D, Banks SL, Gill H, Gupta J, Prausnitz M, Stinchcomb AL.  Proc. Natl. Acad. Sci.  105(6):2058-2063 (2008). PMID: 18250310

Programmable transdermal drug delivery of nicotine using carbon nanotube membranes.  Wu J, Paudel KS, Strasinger C, Hammell DC, Stinchcomb AL, Hinds BJ.  Proc. Natl. Acad. Sci.  107(26):11698-11702 (2010).

In vitro permeation of a pegylated naltrexone prodrug across microneedle-treated skin.  Milewski M, Yerramreddy TR, Ghosh P, Crooks P, Stinchcomb AL.  JControlledRelease.  146(1):37-44 (2010).

Current aspects of formulation efforts and pore lifetime related to microneedle treatment of skin.  Milewski, M, Brogden, N, Stinchcomb, AL.  Expert Opinion on Drug Delivery.  7(5):617-29 (2010). PMID: 20205604.  PMCID: 2858255.

Transdermal delivery of naltrexol and skin permeability lifetime after microneedle treatment in hairless guinea pigs in vivo.  Banks SL, Pinninti RR, Gill HS, Paudel KS, Crooks PA, Brogden NK, Prausnitz MR, Stinchcomb AL.  JPharmSci.  99(7):3072-80 (2010).  PMID: 20166200. PMCID: 2862091.

Diclofenac enables prolonged delivery of naltrexone through microneedle treated skin.  Banks SL, Paudel KS, Brogden NK, Loftin CD, Stinchcomb AL.  PharmRes.  28(5):1211-9(2011).  PMID: 21301935.

Development of a codrug approach for sustained drug delivery across microneedle-treated skin.  Ghosh P, Pinninti RR, Hammell DC, Paudel KS, Stinchcomb AL.  JPharmSci.  102(5), 1458-1467  DOI: 10.1002/jps.23469 (2013).